PDCD1 and non-small cell lung carcinoma: As a result, it was necessary to identify the association between baseline characteristics and clinical outcomes of patients with NSCLC who were treated with PD-1 inhibitors, aiming to elucidate the potential patients that might benefit from PD-1 blockade administration.